<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679679</url>
  </required_header>
  <id_info>
    <org_study_id>Fux-1</org_study_id>
    <nct_id>NCT00679679</nct_id>
  </id_info>
  <brief_title>Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome</brief_title>
  <official_title>Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Privado de Cordoba, Argentina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Privado de Cordoba, Argentina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome is a frequent cause of abnormal menses and infertility. It has also
      been related to cardiovascular disease.

      The objective of this trial is to evaluate the clinical and metabolic efficacy of metformin
      plus life style modifications in women with polycystic ovary syndrome compared with life
      style modifications and placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) is a common and heterogeneous disorder of women in
      reproductive age. It is characterized by hyperandrogenism and chronic anovulation. Several
      studies in diverse populations estimate it's prevalence at 5-10%. Women present, in a high
      percentage of cases, with obesity, hirsutism, acne, menstrual irregularities and infertility.
      Although the exact physiopathology of PCOS remains unknown, several studies tend to point to
      insulinoresistance (IR) as the cause of the syndrome. IR is present in 60 to 70% of patients
      independently of obesity. Compensatory hyperinsulinism has a pivotal role in the
      physiopathogenesis of PCOS. In vitro, insulin stimulates androgen synthesis in thecal cells
      and decrease sex hormone-binding globulin synthesis in the liver, increasing free androgen
      availability.

      Due to the high prevalence of IR, PCOS shares components of metabolic syndrome: abdominal
      obesity, impaired glucose tolerance, gestational and type 2 diabetes, abnormalities in lipid
      profile, blood hypertension, endothelial dysfunction and probably cardiovascular disease.

      In the past, PCOS treatment was focus on ovulation induction for infertility, oral
      contraceptives for irregular bleeding, and androgens antagonists for hirsutism or acne. In
      later years insulin sensitizing agents have been used to reduce hyperinsulinemia, improve
      ovary function and associated metabolic abnormalities. Metformin (MTF), a biguanide, usually
      used in obese patients with type 2 diabetes,inhibits glucose hepatic production,decreases
      insulin secretion and increases peripheral insulin sensitivity.

      Some studies have reported an improvement in insulin sensitivity associated with reduction of
      hyperandrogenism and improvements in reproductive abnormalities with MTF. On the other hand,
      other authors failed to observe those changes. However, an off label indication for it usage
      in PCOS for FDA and the lack of large controlled trials, MTF indication to treat PCOS has
      grown dramatically in later years.

      In obese women with PCOS, weight loss effectively ameliorates hyperandrogenism and metabolic
      disorders by improving insulin resistance.

      Some trials have suggested that those effects could be improved with insulin sensitizing
      agents without changes in body weigh.

      The present study was designed to assess, in a randomized, double-blind, placebo-controlled
      way, the effects of MTF in addition to lifestyle modifications on endocrine and metabolic
      disturbances in women with PCOS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body mass index,Normalization of menses,Pregnancy,Hirsutism,Waist to hip ratio, Testosterone, Androstenedione, DHEAS,Progesterone, FSH, LH,Glucose, OGTT,Insulinemia,Total HDL and LDL Cholesterol, Triglycerides,Uric acid, Prostate specific antigen</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 750 mg BID for 4 months</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>D.B.I. 500 mg. 1 1/2 tables BID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Diet counseling and exercise</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women in reproductive age

          -  With polycystic ovary syndrome defined by hyperandrogenism (elevated serum
             testosterone concentrations), and oligomenorrhea (cycles of 35 days or longer), or
             amenorrhea (no menses in the last 6 months) after negative screening pregnancy test

        Exclusion Criteria:

          -  Pregnancy

          -  Cushing' s syndrome

          -  Late onset congenital adrenal hyperplasia

          -  Androgen-secreting tumors

          -  Uncontrolled thyroid disease

          -  Hyperprolactinemia

          -  Diabetes any

          -  Cardiovascular diseases (Ischaemic heart disease, uncontrolled hypertension, heart
             failure)

          -  Acute or chronic infections at baseline

          -  Renal disease

          -  Liver disease

          -  Had taken any medications for at least 3 months before enrolment in the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolina Fux Otta, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Privado de Córdoba</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004 Jun;89(6):2745-9.</citation>
    <PMID>15181052</PMID>
  </reference>
  <reference>
    <citation>Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000 Jul;85(7):2434-8.</citation>
    <PMID>10902790</PMID>
  </reference>
  <reference>
    <citation>Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999 Nov;84(11):4006-11.</citation>
    <PMID>10566641</PMID>
  </reference>
  <reference>
    <citation>Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005 Mar 24;352(12):1223-36. Review.</citation>
    <PMID>15788499</PMID>
  </reference>
  <reference>
    <citation>Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997 Dec;18(6):774-800. Review.</citation>
    <PMID>9408743</PMID>
  </reference>
  <reference>
    <citation>Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989 Sep;38(9):1165-74.</citation>
    <PMID>2670645</PMID>
  </reference>
  <reference>
    <citation>Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 1986 May;62(5):904-10.</citation>
    <PMID>3514651</PMID>
  </reference>
  <reference>
    <citation>Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991 Jan;72(1):83-9.</citation>
    <PMID>1898744</PMID>
  </reference>
  <reference>
    <citation>Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005 Sep 24-30;366(9491):1059-62.</citation>
    <PMID>16182882</PMID>
  </reference>
  <reference>
    <citation>Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999 Jan;84(1):165-9.</citation>
    <PMID>9920077</PMID>
  </reference>
  <reference>
    <citation>Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003 Jun;88(6):2562-8.</citation>
    <PMID>12788855</PMID>
  </reference>
  <reference>
    <citation>Wild RA. Long-term health consequences of PCOS. Hum Reprod Update. 2002 May-Jun;8(3):231-41. Review.</citation>
    <PMID>12078834</PMID>
  </reference>
  <reference>
    <citation>Dahlgren E, Janson PO, Johansson S, Lapidus L, Odén A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992 Dec;71(8):599-604.</citation>
    <PMID>1336918</PMID>
  </reference>
  <reference>
    <citation>Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol. 1998 May;51(5):415-22.</citation>
    <PMID>9619969</PMID>
  </reference>
  <reference>
    <citation>Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001 Mar 13;103(10):1410-5.</citation>
    <PMID>11245645</PMID>
  </reference>
  <reference>
    <citation>Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab. 2003 Oct;14(8):365-70. Review.</citation>
    <PMID>14516934</PMID>
  </reference>
  <reference>
    <citation>Matthaei S, Stumvoll M, Kellerer M, Häring HU. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev. 2000 Dec;21(6):585-618. Review.</citation>
    <PMID>11133066</PMID>
  </reference>
  <reference>
    <citation>Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet. 2003 May 31;361(9372):1894-901. Review.</citation>
    <PMID>12788588</PMID>
  </reference>
  <reference>
    <citation>Norman RJ, Homan G, Moran L, Noakes M. Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome. Endocrine. 2006 Aug;30(1):35-43. Review.</citation>
    <PMID>17185790</PMID>
  </reference>
  <reference>
    <citation>Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN; PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001 Apr;86(4):1626-32.</citation>
    <PMID>11297595</PMID>
  </reference>
  <reference>
    <citation>Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994 May;43(5):647-54.</citation>
    <PMID>8177055</PMID>
  </reference>
  <reference>
    <citation>Tepper SL, Jagirdar J, Heath D, Geller SA. Homology between the female paraurethral (Skene's) glands and the prostate. Immunohistochemical demonstration. Arch Pathol Lab Med. 1984 May;108(5):423-5.</citation>
    <PMID>6546868</PMID>
  </reference>
  <reference>
    <citation>Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab. 1994 Jun;78(6):1536-9.</citation>
    <PMID>7515392</PMID>
  </reference>
  <reference>
    <citation>Cassidenti DL, Paulson RJ, Serafini P, Stanczyk FZ, Lobo RA. Effects of sex steroids on skin 5 alpha-reductase activity in vitro. Obstet Gynecol. 1991 Jul;78(1):103-7.</citation>
    <PMID>1828548</PMID>
  </reference>
  <reference>
    <citation>Escobar-Morreale HF, Serrano-Gotarredona J, Avila S, Villar-Palasí J, Varela C, Sancho J. The increased circulating prostate-specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. J Clin Endocrinol Metab. 1998 Jul;83(7):2580-4.</citation>
    <PMID>9661648</PMID>
  </reference>
  <reference>
    <citation>Kuhl H. Comparative pharmacology of newer progestogens. Drugs. 1996 Feb;51(2):188-215. Review.</citation>
    <PMID>8808163</PMID>
  </reference>
  <reference>
    <citation>Zarghami N, Grass L, Sauter ER, Diamandis EP. Prostate-specific antigen in serum during the menstrual cycle. Clin Chem. 1997 Oct;43(10):1862-7.</citation>
    <PMID>9342005</PMID>
  </reference>
  <reference>
    <citation>Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2003 Jan;88(1):148-56.</citation>
    <PMID>12519844</PMID>
  </reference>
  <reference>
    <citation>Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003 Oct 25;327(7421):951-3. Review.</citation>
    <PMID>14576245</PMID>
  </reference>
  <reference>
    <citation>Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003;(3):CD003053. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD003053.</citation>
    <PMID>12917943</PMID>
  </reference>
  <reference>
    <citation>Guzelmeric K, Seker N, Unal O, Turan C. High serum prostate-specific antigen concentrations in hirsute women do not decrease with treatment by the combination of spironolactone and the contraceptive pill. Gynecol Endocrinol. 2004 Oct;19(4):190-5.</citation>
    <PMID>15724801</PMID>
  </reference>
  <reference>
    <citation>Escobar-Morreale HF, Avila S, Sancho J. Serum prostate-specific antigen concentrations are not useful for monitoring the treatment of hirsutism with oral contraceptive pills. J Clin Endocrinol Metab. 2000 Jul;85(7):2488-92.</citation>
    <PMID>10902798</PMID>
  </reference>
  <reference>
    <citation>Bahceci M, Bilge M, Tuzcu A, Tuzcu S, Bahceci S. Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel/ethinyl estradiol combination. J Endocrinol Invest. 2004 Apr;27(4):353-6.</citation>
    <PMID>15233555</PMID>
  </reference>
  <reference>
    <citation>Negri C, Tosi F, Dorizzi R, Fortunato A, Spiazzi GG, Muggeo M, Castello R, Moghetti P. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab. 2000 Jan;85(1):81-4.</citation>
    <PMID>10634368</PMID>
  </reference>
  <reference>
    <citation>Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007 Feb;92(2):405-13. Epub 2006 Nov 7.</citation>
    <PMID>17090633</PMID>
  </reference>
  <reference>
    <citation>Güllü S, Emral R, Asik M, Cesur M, Tonyukuk V. Diagnostic value of prostatic specific antigen in hirsute women. J Endocrinol Invest. 2003 Dec;26(12):1198-202.</citation>
    <PMID>15055472</PMID>
  </reference>
  <reference>
    <citation>Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7. Review.</citation>
    <PMID>14688154</PMID>
  </reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2008</study_first_submitted>
  <study_first_submitted_qc>May 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2008</study_first_posted>
  <last_update_submitted>May 16, 2008</last_update_submitted>
  <last_update_submitted_qc>May 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Carolina Fux Otta</name_title>
    <organization>Hospital Privado de Córdoba, Argentina</organization>
  </responsible_party>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>Treatment</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 22, 2009</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>January 23, 2009</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>February 9, 2009</submitted>
    <returned>March 9, 2009</returned>
    <submitted>March 16, 2009</submitted>
    <returned>April 21, 2009</returned>
    <submitted>August 3, 2009</submitted>
    <returned>September 4, 2009</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

